RCUS

Arcus Biosciences, Inc. (RCUS) | Rumor.io

Arcus Biosciences

RCUS

Attention (50-day avg)0%

Attention rank (50-day avg)#2,305

Bullish sentiment (50-day avg)94%

Price to earnings ratio-7.61

Market capitalization3.1B

Earnings per share-3.94

Dividend yield (TTM)—

Revenue (annual)247M

Net income (annual)-353M

Social

What share of all stock conversation is about RCUS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% 0	0% 0

Jun 27

Arcus Biosciences, Inc. ($RCUS) is expected to have a significant increase in message volume.
The post does not provide further context or details about the expected increase in message volume.
There is no additional market-relevant information provided in the post.

Generated by AI

Sentiment

Of the messages about RCUS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	62.5% -37.5	83.86% -2.36
Bearish	—	—	37.5% new	16.14% +2.36

Aug 23

Arcus Biosciences is showing significant growth potential, with a 12% move in after-hours trading and a 31% increase in price.
Analysts are highly confident in the company's prospects, with a 83% buy consensus from 18 analysts and a strong growth forecast of 8.66% yearly EPS growth over the next 5 years.
BTIG and Mizuho have reiterated their "Buy" ratings for Arcus Biosciences, with price targets of $70 and $51, respectively, indicating a strong valuation of the company.

Generated by AI

Topics

Of the messages about RCUS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	3.57%	60.32%
Technical Analysis	0%	0%	75%	19.04%
Analysts	0%	0%	21.43%	14.59%
Controversies	0%	0%	0%	0.25%
Earnings	0%	0%	0%	1.36%
Macro	0%	0%	0%	4.45%

Announcements· Jun 20

Mainz Biomed has unveiled multimodal cancer screening tests at ASCO 2024, integrating AI and mRNA biomarkers for enhanced precision.
No information about Arcus Biosciences, Inc. (RCUS) is provided in the post.
No market-relevant information is mentioned in the post.

Technical Analysis· Apr 17

$RCUS's MACD Histogram has turned positive, indicating a potential uptrend.
The stock is being considered for a day 2 play, as it had a strong day yesterday and could continue to be in play today.
The stock's recent price action suggests it may be worth considering for technical analysis.

Generated by AI

Community

Of the messages about RCUS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	50%	26.67%	65.75%
Newcomers	0%	50%	73.33%	34.25%

Regulars· Feb 18

Arcus Biosciences' shares are down 0.50 following a 13.6M share secondary offering priced at $11.00, a new low for the year at $11.55.
BofA has raised their price target on $RCUS to $17, but still sees the shares as fairly valued and reiterate a Neutral rating, citing long-standing pipeline concerns.
Arcus Biosciences has retained rights to casdatifan, a potential best-in-class HIF-2α inhibitor, and priced a $150M common stock offering, with MORGANSTANLEY analyst Terence Flynn downgrading his price target from $36 to $25.

Newcomers· Jan 30

Newcomers are observing a significant price gap between Arcus Biosciences ($RCUS) and Gilead ($GILD), with $RCUS stock seemingly undervalued compared to $GILD's investment.
Analysts, such as Mr. Market and #WEDBUSH's Robert Driscoll, are downgrading their price targets for $RCUS, citing concerns over the company's potential upside and valuation.
The amended collaboration between Gilead ($GILD) and Arcus Biosciences ($RCUS) has accelerated the development of TIGIT pathway therapies, with Gilead purchasing $320M in $RCUS stocks at $21.00 each.

Generated by AI

HAYWARD, Calif., September 24, 2026--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for the treatment of cancer and inflammatory diseases, today announced that the Compensation Committee of the Company’s Board of Directors granted four new employees options to purchase a total of 21,200 shares of the Company’s common stock at an exercise price per share of $26.39, which was the closi

5d agoYahoo! Finance Canada

TD Cowen Initiates Arcus Biosciences at Buy

Arcus Biosciences (RCUS) has an average rating of buy and mean price target of $39.27, according to

14d agofinance.yahoo.com

Also Discussed

Investors talking about RCUS also mention

#	Name	Attention
1	Cullinan Therapeutics Inc.CGEM	0%new
2	Relay Therapeutics Inc.RLAY	0%new
3	Nurix Therapeutics, Inc.NRIX	0%new
4	Kulicke & Soffa Industries, Inc.KLIC	0%0
5	Kymera Therapeutics Inc.KYMR	0%0
6	Cohu, Inc.COHU	0.01%-0.03
7	Extreme Networks Inc.EXTR	0%new
8	Tango Therapeutics Inc.TNGX	0%new
9	Xometry Inc.XMTR	0%new
10	Ultra Clean Holdings, Inc.UCTT	0%0

Arcus Biosciences, Inc.

Healthcare
Biotechnology

Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing cancer immunotherapies and combination medicines. The company is building a portfolio of differentiated small molecules and antibodies designed to target key biological pathways involved in tumor growth and immune response. Its current work centers on oncology programs across several solid tumor areas, including lung, gastrointestinal, kidney, and pancreatic cancers. Arcus Biosciences also develops therapies intended to improve how cancer treatments are combined and used in clinical practice, with an emphasis on novel mechanisms such as immuno-oncology and targeted oncology. Headquartered in Hayward, California, Arcus Biosciences operates as a research-driven company working with collaborators to advance investigational medicines through clinical development and toward potential commercialization.

Website

Location

3928 Point Eden Way

Hayward, CA, 94545

United States

Social

What share of all stock conversation is about RCUS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% 0	0% 0

Jun 27

Arcus Biosciences, Inc. ($RCUS) is expected to have a significant increase in message volume.
The post does not provide further context or details about the expected increase in message volume.
There is no additional market-relevant information provided in the post.

Generated by AI

Sentiment

Of the messages about RCUS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	62.5% -37.5	83.86% -2.36
Bearish	—	—	37.5% new	16.14% +2.36

Aug 23

Arcus Biosciences is showing significant growth potential, with a 12% move in after-hours trading and a 31% increase in price.
Analysts are highly confident in the company's prospects, with a 83% buy consensus from 18 analysts and a strong growth forecast of 8.66% yearly EPS growth over the next 5 years.
BTIG and Mizuho have reiterated their "Buy" ratings for Arcus Biosciences, with price targets of $70 and $51, respectively, indicating a strong valuation of the company.

Generated by AI

Topics

Of the messages about RCUS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	3.57%	60.32%
Technical Analysis	0%	0%	75%	19.04%
Analysts	0%	0%	21.43%	14.59%
Controversies	0%	0%	0%	0.25%
Earnings	0%	0%	0%	1.36%
Macro	0%	0%	0%	4.45%

Announcements· Jun 20

Mainz Biomed has unveiled multimodal cancer screening tests at ASCO 2024, integrating AI and mRNA biomarkers for enhanced precision.
No information about Arcus Biosciences, Inc. (RCUS) is provided in the post.
No market-relevant information is mentioned in the post.

Technical Analysis· Apr 17

$RCUS's MACD Histogram has turned positive, indicating a potential uptrend.
The stock is being considered for a day 2 play, as it had a strong day yesterday and could continue to be in play today.
The stock's recent price action suggests it may be worth considering for technical analysis.

Generated by AI

Community

Of the messages about RCUS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	50%	26.67%	65.75%
Newcomers	0%	50%	73.33%	34.25%

Regulars· Feb 18

Arcus Biosciences' shares are down 0.50 following a 13.6M share secondary offering priced at $11.00, a new low for the year at $11.55.
BofA has raised their price target on $RCUS to $17, but still sees the shares as fairly valued and reiterate a Neutral rating, citing long-standing pipeline concerns.
Arcus Biosciences has retained rights to casdatifan, a potential best-in-class HIF-2α inhibitor, and priced a $150M common stock offering, with MORGANSTANLEY analyst Terence Flynn downgrading his price target from $36 to $25.

Newcomers· Jan 30

Newcomers are observing a significant price gap between Arcus Biosciences ($RCUS) and Gilead ($GILD), with $RCUS stock seemingly undervalued compared to $GILD's investment.
Analysts, such as Mr. Market and #WEDBUSH's Robert Driscoll, are downgrading their price targets for $RCUS, citing concerns over the company's potential upside and valuation.
The amended collaboration between Gilead ($GILD) and Arcus Biosciences ($RCUS) has accelerated the development of TIGIT pathway therapies, with Gilead purchasing $320M in $RCUS stocks at $21.00 each.

Generated by AI

Arcus Biosciences

Social

Jun 27

Sentiment

Aug 23

Topics

Announcements· Jun 20

Technical Analysis· Apr 17

Community

Regulars· Feb 18

Newcomers· Jan 30

News

Arcus Biosciences Announces New Employment Inducement Grants

Cantor Fitzgerald reiterates Arcus Biosciences stock rating

Arcus Biosciences stock gains on TD Cowen buy rating

Why is Arcus Biosciences stock rallying today?

Arcus Biosciences stock initiated at Buy by TD Cowen on RCC drug

TD Cowen Initiates Arcus Biosciences at Buy

Also Discussed

Arcus Biosciences, Inc.

Company Information

Location

News

Arcus Biosciences Announces New Employment Inducement Grants

Cantor Fitzgerald reiterates Arcus Biosciences stock rating

Arcus Biosciences stock gains on TD Cowen buy rating

Why is Arcus Biosciences stock rallying today?

Arcus Biosciences stock initiated at Buy by TD Cowen on RCC drug

TD Cowen Initiates Arcus Biosciences at Buy

Also Discussed

Social

Jun 27

Sentiment

Aug 23

Topics

Announcements· Jun 20

Technical Analysis· Apr 17

Community

Regulars· Feb 18

Newcomers· Jan 30